The Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) has received the Egyptian Drug Authority (EDA) approval to price its antiviral Anviziram for treatment of the novel coronavirus (COVID-19) cases.
Rameda started last month manufacturing Anviziram, which contains the active pharmaceutical ingredient Favipiravir which has been adopted as part of the COVID-19 treatment protocol in Russia, China, and India. It will be released at EGP 1,260 per 40-tablet package.
The company has also obtained the EDA approval for pricing another COVID-19 drug, Remdesivir, which is produced in ampoule form for intravenous injection.
Remdesivir is also intended for use in the treatment of coronavirus patients, with the product sold in powder form under the trademark Remdesivir Rameda, at a price of EGP 680.
Rameda had obtained the EDA approval to start manufacturing Remdesivir in June, with the company intending to launch the first batch of the drug in September.
Remdesivir is a broad-spectrum antiviral that has been used in the treatment of critical coronavirus cases. Rameda is the first company to manufacture Remdesivir in the form of ampoules containing dried powder that can be kept at normal room temperature.